These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 30281083)
1. Drug-free Holidays: Compliance, Tolerability, and Acceptability of a 3-Day Atovaquone/Proguanil Schedule for Pretravel Malaria Chemoprophylaxis in Australian Travelers. Lau CL; Ramsey L; Mills LC; Furuya-Kanamori L; Mills DJ Clin Infect Dis; 2019 Jun; 69(1):137-143. PubMed ID: 30281083 [TBL] [Abstract][Full Text] [Related]
2. Assessment of adherence to atovaquone-proguanil prophylaxis in travelers. DePetrillo JC; Singer C; Bergagnini IA; Kolakowski P; Edwards B; Smith MA J Travel Med; 2010; 17(4):217-20. PubMed ID: 20636593 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of short prophylactic course of atovaquone-proguanil in travelers to sub-saharan Africa. Leshem E; Meltzer E; Stienlauf S; Kopel E; Schwartz E J Travel Med; 2014; 21(2):82-5. PubMed ID: 24298915 [TBL] [Abstract][Full Text] [Related]
4. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review. Savelkoel J; Binnendijk KH; Spijker R; van Vugt M; Tan K; Hänscheid T; Schlagenhauf P; Grobusch MP Travel Med Infect Dis; 2018; 21():3-20. PubMed ID: 29242073 [TBL] [Abstract][Full Text] [Related]
5. Questionnaire-based analysis of atovaquone-proguanil compared with mefloquine in the chemoprophylaxis of malaria in non-immune Japanese travelers. Kato T; Okuda J; Ide D; Amano K; Takei Y; Yamaguchi Y J Infect Chemother; 2013 Feb; 19(1):20-3. PubMed ID: 22740189 [TBL] [Abstract][Full Text] [Related]
6. Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options. Meltzer E; Rahav G; Schwartz E Clin Infect Dis; 2018 May; 66(11):1751-1755. PubMed ID: 29228132 [TBL] [Abstract][Full Text] [Related]
7. Malaria chemoprophylaxis with atovaquone-proguanil: is a shorter regimen fully protective? Grobusch MP J Travel Med; 2014; 21(2):79-81. PubMed ID: 24593022 [No Abstract] [Full Text] [Related]
8. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. Overbosch D J Travel Med; 2003 May; 10 Suppl 1():S16-20; discussion S21-3. PubMed ID: 12737756 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark. Kofoed K; Petersen E J Travel Med; 2003; 10(3):150-4. PubMed ID: 12757688 [TBL] [Abstract][Full Text] [Related]
10. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. Deye GA; Miller RS; Miller L; Salas CJ; Tosh D; Macareo L; Smith BL; Fracisco S; Clemens EG; Murphy J; Sousa JC; Dumler JS; Magill AJ Clin Infect Dis; 2012 Jan; 54(2):232-9. PubMed ID: 22052893 [TBL] [Abstract][Full Text] [Related]
11. Use of malaria prevention measures by North American and European travelers to East Africa. Lobel HO; Baker MA; Gras FA; Stennies GM; Meerburg P; Hiemstra E; Parise M; Odero M; Waiyaki P J Travel Med; 2001; 8(4):167-72. PubMed ID: 11703900 [TBL] [Abstract][Full Text] [Related]
12. The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. Petersen E J Travel Med; 2003 May; 10 Suppl 1():S13-5; discussion S21. PubMed ID: 12737755 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone®) in long-term travellers to West Africa. Lachish T; Bar-Meir M; Eisenberg N; Schwartz E J Travel Med; 2016 Jun; 23(6):. PubMed ID: 27625401 [TBL] [Abstract][Full Text] [Related]
14. Malaria chemoprophylaxis regimens: a descriptive drug utilization study. Bloechliger M; Schlagenhauf P; Toovey S; Schnetzler G; Tatt I; Tomianovic D; Jick SS; Meier CR Travel Med Infect Dis; 2014; 12(6 Pt B):718-25. PubMed ID: 24934849 [TBL] [Abstract][Full Text] [Related]
15. Failure of atovaquone-proguanil malaria chemoprophylaxis in a traveler to Ghana. Boggild AK; Lau R; Reynaud D; Kain KC; Gerson M Travel Med Infect Dis; 2015; 13(1):89-93. PubMed ID: 25582377 [TBL] [Abstract][Full Text] [Related]
16. Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. Toovey S; Nieforth K; Smith P; Schlagenhauf P; Adamcova M; Tatt I; Tomianovic D; Schnetzler G Travel Med Infect Dis; 2014; 12(6 Pt B):726-32. PubMed ID: 25443997 [TBL] [Abstract][Full Text] [Related]
17. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Camus D; Djossou F; Schilthuis HJ; Høgh B; Dutoit E; Malvy D; Roskell NS; Hedgley C; De Boever EH; Miller GB; Clin Infect Dis; 2004 Jun; 38(12):1716-23. PubMed ID: 15227617 [TBL] [Abstract][Full Text] [Related]
18. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Høgh B; Clarke PD; Camus D; Nothdurft HD; Overbosch D; Günther M; Joubert I; Kain KC; Shaw D; Roskell NS; Chulay JD; Lancet; 2000 Dec; 356(9245):1888-94. PubMed ID: 11130385 [TBL] [Abstract][Full Text] [Related]
19. The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected]. van Genderen PJ; Koene HR; Spong K; Overbosch D J Travel Med; 2007; 14(2):92-5. PubMed ID: 17367478 [TBL] [Abstract][Full Text] [Related]